Location History:
- Shiroishi-ku, Sapporo, JP (2010)
- Sapporo, JP (2016)
Company Filing History:
2 out of 26 
2 out of 950 
3 out of 832,912 Years Active: 2010-2016
Title: Innovations in Cancer Research: The Contributions of Shin-ichi Fukumoto
Introduction
Shin-ichi Fukumoto, an esteemed inventor based in Sapporo, Japan, has made significant strides in the field of cancer research. With a total of three patents to his name, Fukumoto's work is pivotal in the ongoing fight against cancer, particularly in the development of diagnostic and therapeutic tools.
Latest Patents
Fukumoto's latest patents focus on a gene that is overexpressed in cancer. The inventions include a protein encoded by a gene having a nucleotide sequence represented by any of SEQ ID NOs: 1 to 65 or a fragment thereof. This also encompasses an antibody recognizing the protein or an antigen-binding fragment thereof. Furthermore, the patents include a polynucleotide featuring at least 12 consecutive nucleotides from the mentioned gene sequences, which are instrumental in diagnosing and treating cancer. Notably, the gene and the protein discovered through this research hold great promise for enhancing cancer diagnostics and therapies.
Career Highlights
Throughout his career, Fukumoto has worked with notable companies, including Perseus Proteomics Inc. His expertise and innovative mindset have played a crucial role in the advancement of scientific knowledge and applications in the field of oncology.
Collaborations
Fukumoto has collaborated with esteemed colleagues such as Hiroyuki Aburatani and Yoshitaka Hippo. These partnerships encompass a range of research endeavors that aim to push the boundaries of current cancer treatment methods and improve patient outcomes.
Conclusion
In summary, Shin-ichi Fukumoto’s contributions to cancer research through his innovative patents are noteworthy. His work not only demonstrates the potential of gene-focused therapies but also highlights the importance of collaboration in tackling complex scientific challenges. As research continues to progress, Fukumoto’s findings may pave the way for more effective diagnostic and treatment options for cancer patients globally.